FDA Approves Cosibelimab for Cutaneous SCCDecember 17, 2024Nonmelanoma Skin CancerPatient & Survivor Care
New Cancer Drugs: Do Patients Prefer Faster Access or Clinical Benefit?December 12, 2024Patient & Survivor CarePractice ManagementMixed TopicsBreast CancerCNS/Brain CancerDLBCLFollicular Lymphoma
FDA Approves Durvalumab for Limited-Stage SCLCDecember 6, 2024Lung CancerImmunotherapyPatient & Survivor CarePractice Management
FDA Approves Bizengri for NSCLC and Pancreatic Cancers Harboring NRG1 Gene FusionDecember 5, 2024Lung CancerPatient & Survivor CareGastrointestinal CancerMixed TopicsGastroenterology
FDA Approves Bispecific HER2 Antibody for Biliary Tract CancerNovember 22, 2024Gastrointestinal CancerGastroenterologyPatient & Survivor Care
Gotistobart Trial for NSCLC on Partial Clinical HoldOctober 23, 2024Lung CancerPatient & Survivor CarePractice Management
FDA Panel Votes for Limits on Gastric, Esophageal Cancer ImmunotherapySeptember 30, 2024Gastrointestinal CancerGastroenterologyPractice ManagementImmunotherapyPatient & Survivor Care
FDA Okays Osimertinib After CRT in Locally Advanced, Unresectable NSCLCSeptember 27, 2024Lung CancerPatient & Survivor CarePractice Management
FDA Expands Indication for Amivantamab in Lung CancerSeptember 23, 2024Lung CancerPractice Management
FDA OKs Adjuvant Ribociclib in Earlier Stage Breast CancerSeptember 23, 2024Breast CancerPatient & Survivor Care
FDA OKs Subcutaneous Atezolizumab Formulation for Multiple Cancer IndicationsSeptember 17, 2024Mixed TopicsMelanomaLung CancerSarcoma & GISTPatient & Survivor CarePractice Management
FDA OKs First-Line Lazertinib With Amivantamab for NSCLCAugust 22, 2024Lung CancerPractice Management
FDA Approves Lymphir for R/R Cutaneous T-Cell LymphomaAugust 9, 2024Patient & Survivor CareImmunotherapyLymphoma & Plasma Cell DisordersImmuno-oncologyPractice Management
